183 related articles for article (PubMed ID: 10822396)
1. Dosage escalation of intravesical oxybutynin in the treatment of neurogenic bladder patients.
Haferkamp A; Staehler G; Gerner HJ; Dörsam J
Spinal Cord; 2000 Apr; 38(4):250-4. PubMed ID: 10822396
[TBL] [Abstract][Full Text] [Related]
2. [Intravesical oxybutynin in children with meningomyelocele. Efficient treatment with few side-effects].
Von Zweigbergk M; Nordin B; Jonsson S
Lakartidningen; 1996 Oct; 93(41):3573-6. PubMed ID: 8965514
[No Abstract] [Full Text] [Related]
3. Follow-up of long-time treatment with intravesical oxybutynin for neurogenic bladder in children.
Amark P; Bussman G; Eksborg S
Eur Urol; 1998 Aug; 34(2):148-53. PubMed ID: 9693251
[TBL] [Abstract][Full Text] [Related]
4. Effect of intermittent urethral catheterization and oxybutynin bladder instillation on urinary continence status and quality of life in a selected group of spinal cord injury patients with neuropathic bladder dysfunction.
Vaidyananthan S; Soni BM; Brown E; Sett P; Krishnan KR; Bingley J; Markey S
Spinal Cord; 1998 Jun; 36(6):409-14. PubMed ID: 9648197
[TBL] [Abstract][Full Text] [Related]
5. Side-effects of oral or intravesical oxybutynin chloride in children with spina bifida.
Ferrara P; D'Aleo CM; Tarquini E; Salvatore S; Salvaggio E
BJU Int; 2001 May; 87(7):674-8. PubMed ID: 11350411
[TBL] [Abstract][Full Text] [Related]
6. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury.
O'Leary M; Erickson JR; Smith CP; McDermott C; Horton J; Chancellor MB
J Spinal Cord Med; 2003; 26(2):159-62. PubMed ID: 12828295
[TBL] [Abstract][Full Text] [Related]
7. Intravesical instillation of oxybutynin hydrochloride therapy for patients with a neuropathic bladder.
Mizunaga M; Miyata M; Kaneko S; Yachiku S; Chiba K
Paraplegia; 1994 Jan; 32(1):25-9. PubMed ID: 8015832
[TBL] [Abstract][Full Text] [Related]
8. Early cystometrograms can predict the response to intravesical instillation of oxybutynin chloride in myelomeningocele patients.
Connor JP; Betrus G; Fleming P; Perlmutter AD; Reitelman C
J Urol; 1994 Apr; 151(4):1045-7. PubMed ID: 8126787
[TBL] [Abstract][Full Text] [Related]
9. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, efficacy, and safety of intravesical formulation of oxybutynin in patients with detrusor overactivity.
Lehtoranta K; Tainio H; Lukkari-Lax E; Hakonen T; Tammela TL
Scand J Urol Nephrol; 2002 Feb; 36(1):18-24. PubMed ID: 12002352
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of intravesical oxybutynin in children with detrusor-sphincter dyssynergia: with special reference to age-dependent parameters.
Humblet M; Verpoorten C; Christiaens MH; Hirche H; Jansen K; Buyse G; van Gool JD
Neurourol Urodyn; 2015 Apr; 34(4):336-42. PubMed ID: 24436114
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study.
Kennelly MJ; Lemack GE; Foote JE; Trop CS
Urology; 2009 Oct; 74(4):741-5. PubMed ID: 19628264
[TBL] [Abstract][Full Text] [Related]
13. The use of intravesical oxybutynin chloride in children with neurogenic bladder.
Greenfield SP; Fera M
J Urol; 1991 Aug; 146(2 ( Pt 2)):532-4. PubMed ID: 1861294
[TBL] [Abstract][Full Text] [Related]
14. Intravesical therapy for the treatment of neurogenic bladder in children.
Holland AJ; King PA; Chauvel PJ; O'Neill MK; McKnight DL; Barker AP
Aust N Z J Surg; 1997 Oct; 67(10):731-3. PubMed ID: 9322726
[TBL] [Abstract][Full Text] [Related]
15. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder.
Kaplinsky R; Greenfield S; Wan J; Fera M
J Urol; 1996 Aug; 156(2 Pt 2):753-6. PubMed ID: 8683776
[TBL] [Abstract][Full Text] [Related]
16. Intravesical application of a stable oxybutynin solution improves therapeutic compliance and acceptance in children with neurogenic bladder dysfunction.
Buyse G; Verpoorten C; Vereecken R; Casaer P
J Urol; 1998 Sep; 160(3 Pt 2):1084-7; discussion 1092. PubMed ID: 9719281
[TBL] [Abstract][Full Text] [Related]
17. Complications of intravesical oxybutynin chloride therapy in the pediatric myelomeningocele population.
Palmer LS; Zebold K; Firlit CF; Kaplan WE
J Urol; 1997 Feb; 157(2):638-40. PubMed ID: 8996387
[TBL] [Abstract][Full Text] [Related]
18. [The use of intravesical oxybutynin hydrochloride in patients with neurogenic bladder managed by intermittent catheterization].
Yokoyama O; Ishiura Y; Nakamura Y; Ohkawa M
Hinyokika Kiyo; 1995 Jul; 41(7):521-4. PubMed ID: 7668182
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and effects of intravesical oxybutynin on the paediatric neurogenic bladder.
Amark P; Eksborg S; Juneskans O; Bussman G; Palm C
Br J Urol; 1998 Dec; 82(6):859-64. PubMed ID: 9883225
[TBL] [Abstract][Full Text] [Related]
20. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury.
Pannek J; Sommerfeld HJ; Bötel U; Senge T
Urology; 2000 Mar; 55(3):358-62. PubMed ID: 10699610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
